Biomarkers of COVID-19: red blood cells by BIOMEDICA CRO
A review published in Biomarkers in Medicine highlights the prospects and challenges of RDW as a predictive biomarker for viral infections, with a special focus on coronavirus disease 2019 (COVID-19) and hepatitis B, HIV/AIDS, Epstein–Barr virus infectious mononucleosis.
The findings of the study demonstrate that RDW can predict the severity and progression of viral hepatitis and COVID-19 with high sensitivity and specificity. It is a cost-effective and accessible parameter that can help reduce morbidity and mortality in the developing world, where resources are scarce. Further research focusing on overcoming the current limitations is necessary to ensure the universal application of RDW as a predictive prognostic biomarker for emerging viral infections.
This highlights the importance of standardizing existing protocols to evaluate RDW as a prognostic biomarker for COVID-19. In terms of diagnostics, RDW could differentiate between COVID-19 and other types of pneumonia.
Please follow the link for more info.
BIOMEDICA CRO is proud to take a part in preclinical studies and researching of new biomarkers. We are ready to collect high-quality human biospecimens to provide scientists with all needed samples and associated data for their studies. Please email us to start our collaboration: office@biomedica-cro.com or visit our page with relevant biospecimens options.
